Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
about
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsEMT, CTCs and CSCs in tumor relapse and drug-resistanceThe HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.Circulating tumor cells in breast cancer.The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization.Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticityHER2 and breast cancer stem cells: more than meets the eye.Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.Cell type of origin as well as genetic alterations contribute to breast cancer phenotypesA FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolationHER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer.Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Recent advances in the molecular characterization of circulating tumor cells.Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.Circulating tumor cells as therapy-related biomarkers in cancer patients.Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies.Circulating tumour cells and cell-free DNA as tools for managing breast cancer.Luminal breast cancer: from biology to treatment.Circulating tumor cells as promising novel biomarkers in solid cancers.Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy.Review: circulating tumor cells in the practice of breast cancer oncology.Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets.Gene expression profiling and DNA methylation analyses of CTCs.Circulating tumor cells in breast cancer: applications in personalized medicine.Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer.Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.Circulating tumor cells: clinical validity and utility.Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck.Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.Tumor Heterogeneity in Breast Cancer.
P2860
Q26827936-C4176868-F6FF-4843-BB5A-B26F072B05FDQ28082935-8B5D4C8A-B360-4755-A28A-C541AE15C602Q33769034-49056AFD-5750-47F9-B5A7-92070054698CQ34077349-269249A1-0C9C-428F-A411-3E0901F6C9A0Q34564188-527BC759-C416-4A76-A361-97CDF6A2B26EQ35124176-F127D54C-55E2-4C06-97C5-8A73F1F0B9D7Q35320325-AA626A82-C5D5-4CED-9B17-68E0C0E9E781Q35427994-88EF6F78-E206-40F2-B831-15AA3DD645BDQ35665814-A7DE5CDD-22B0-4841-947A-F7C1C80DC857Q35749122-D4229978-925F-4CAE-B853-2361890D8E0CQ35832288-07D74CE6-641A-440E-B6EE-38A63DF6A236Q36206190-830E2010-DBCD-4FB0-99E4-ACAC082C5BDCQ36693285-16141FF4-77BD-48DB-8209-CAAC678FEE27Q36902974-1FD45174-ACAE-4FD1-B6F4-82045DFE77BBQ36925557-221DD36A-47E5-4BE2-8133-FA23C45BEC10Q36959162-714F1377-4108-4EEF-80A4-94185BE9D4A8Q37349280-43B3D2AE-73A7-4373-9579-8170FF996784Q37693504-D0350C2C-90B4-4CAE-AB4C-DA7ED0C59295Q37706346-5995E48C-808E-497D-9788-35241430A5B6Q38073601-AD2A08D5-DCC5-4363-975B-2004F9B8D0A6Q38097525-20EF8DFE-280A-41E4-AB25-B0C04B642F59Q38109808-CD530B7B-C7DE-4C43-83B6-C8389D32EFA8Q38123680-539C8CFE-CD32-4B30-B2F1-4E3F26272E23Q38196920-81B89EBE-7D32-4CFE-A28B-7F65C77B305FQ38261856-A64EDE86-4EF5-4D7E-81EB-27D0B80FCEF4Q38326102-A33A8499-3FAF-4F59-B8AF-D4B9F83FD6ACQ38547813-67C36058-07AF-4985-80FC-A97AE07F45EAQ38662712-6AF02A94-2969-42AC-A431-0F52F27FC0C0Q38716256-42FD6304-89D8-45C7-9FAA-EBE4424335B6Q38734877-7F66B65D-59CA-416C-A5F0-42F001DFFF23Q38985771-01A5269C-889A-4D9C-8DB8-8D94C52A896EQ39022352-C5E7304E-4EED-4C67-9F36-DC6E2BEFA2E0Q39027480-B0337C44-11AA-44E5-AEAE-78829AA52E36Q39151285-000D1AFD-D2C7-44D8-9339-79A66B7486B6Q39154821-D348396C-41F2-4F8E-9074-6923CB51B894Q41047711-532A5CFA-74BD-4C93-84BE-080C0920069BQ41763224-44ADECFF-B983-44BC-8C75-BBD3C3036CCFQ42372003-9787F39D-3A34-4807-AC4E-ACED0C9CC1CDQ44503403-B474533E-3E26-438B-A241-8736422EE7A9Q47146956-7E5813CE-06D8-44CC-ABF6-9C49A6718249
P2860
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Trastuzumab decreases the inci ...... f a randomized phase II study.
@en
Trastuzumab decreases the inci ...... f a randomized phase II study.
@nl
type
label
Trastuzumab decreases the inci ...... f a randomized phase II study.
@en
Trastuzumab decreases the inci ...... f a randomized phase II study.
@nl
prefLabel
Trastuzumab decreases the inci ...... f a randomized phase II study.
@en
Trastuzumab decreases the inci ...... f a randomized phase II study.
@nl
P2093
P2860
P356
P1433
P1476
Trastuzumab decreases the inci ...... of a randomized phase II study
@en
P2093
D Mavroudis
K Kalbakis
S Apostolaki
V Bozionelou
V Georgoulias
P2860
P304
P356
10.1093/ANNONC/MDS020
P577
2012-02-29T00:00:00Z